31-40 of 77 results
Allens acts for Healthscope on Asian pathology sale
Allens has advised Healthscope Limited, one of Australia's leading private healthcare operators, on the sale of its Asian pathology operations in Singapore, Malaysia and Vietnam to funds managed by ...
Competition news
In Touch looks at what's been happening in Competition this month and what it means for your business ...
Allens advises Clearskincare on $127.4m acquisition
Allens has advised the founders of Clearskincare on the sale of the brand's clinic and products businesses to Australian Pharmaceutical Industries (API) for $127.4 million. Under the deal, API will ...
Making sense of human cell and tissue products regulation
The Therapeutic Goods Administration has released guidance on recent changes to the regulation of human cell and tissue products Special Counsel Ric Morgan and Senior Associate Tracy Lu dissect the complex regulatory framework particularly in relation to advertising ...
ACCC's Enforcement and Compliance priorities for 2017
Criminal cartels unfair contract terms consumer guarantees and the health construction and agriculture sectors are some of the ACCCs key enforcement and compliance priorities for 2017 ACCC Chairman Rod Sims released the ACCCs 2017 Compliance and Enforcement Policy on Friday 24 February 2017 ...
Assessment of biosimilars - Is Australia leading, following or going its own way?
The ongoing lack of certainty about what is required to obtain biosimilar registration in Australia extends to three key issues - Comparability is the new product sufficiently similar to permit it to rely on the reference products safety and efficacy data Extrapolation for which of the indications ...
Protecting investment in biologic medicines - biological medicines, biosimilars and the challenges they pose
This series of articles is directed towards the part of biotech that is pharmaceutical rather than diagnostic or bioengineering technologies and in particular towards biologic medicines ...
What's in a (biosimilar) name?
Because biosimilars and their reference biologic medicine are not identical whether compared to each other or even between biosimilars it is important to know which product has been used ...
Costs before Caution - Australia's unique approach to the interchangeability of biosimilars
Recent developments in Australia suggest that there has been a deliberate prioritisation of the cost benefits of facilitating biosimilar interchangeability over the safety and efficacy risks that can arise when biosimilars are used interchangeably ...
Allens lends a hand to Global Health
Allens has advised the Global Health Investment Fund ( GHIF ), a private investment fund whose mission is to finance late-stage drugs, vaccines and diagnostics for diseases that disproportionately ...